Biotech shares are regarded as highly promising due to the innovative strength of the sector, but they also tend to be subject to drastic price fluctuations both ways. After a long period of consolidation, biotech shares have embarked on a clear upward trend since May 2018. Harald Kober, Senior Fund Manager, explains the reasons for the investors’ optimism.
The performance of European equities in the year to date has been disappointing. While in the USA stock exchanges are going from strength to strength, European share prices have been stagnating. Is it still worth investing in European equities?
Open questions about the processing and leaking of data by the social media giant have triggered a correction among technology companies. Bernhard Ruttenstorfer, fund manager of our technology equity fund, has answered questions regarding facebook et al. in this flash interview.
Interview with Ulrich Eberl, one of the most renowned German-speaking scientific journalists and futurologists. Among the books he has published are “Zukunft 2050 – wie wir schon heute die Zukunft erfinden“ (“Future 2050 – how we are inventing the future today”) and “Smarte Maschinen – wie Künstliche Intelligenz unser Leben verändert“ (“Smart machines – how artificial intelligence changes our lives”).
At this year’s IT trade fair CEBIT, the focus was on robots that support humans in their daily routine; on drones that can be used for difficult jobs in the field such as oil rigs; driverless electro busses that are steered by sensors and accelerate and stop autonomously; and various other technological innovations that are no fiction but have in fact already entered our daily lives. Of what relevance are they for the economy, for companies, for consumers – and for investors?